Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833248 · ClinicalTrials.gov registry record · Phase 3
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT00833248 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 246 participants.
The verdict
NCT00833248, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
Interventions
- DRUG Goserelin
- DRUG Bicalutamide
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833248
The ClinicalTrials.gov registry entry for NCT00833248 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Goserelin is the first listed.
NCT00833248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833248 about?
NCT00833248 is a clinical study titled "Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer". The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it...
What is the current status of trial NCT00833248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2009-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00833248?
The interventions under investigation include: Goserelin (DRUG), Bicalutamide (DRUG), Degarelix (DRUG).
Who is sponsoring clinical trial NCT00833248?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.